BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol. 2001;21:243-253. [PMID: 11397661 DOI: 10.1016/s1386-6532(00)00167-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci. 2004;19:541-546. [PMID: 15308845 DOI: 10.3346/jkms.2004.19.4.541] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
2 Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2:8-16. [PMID: 15968334 DOI: 10.7150/ijms.2.8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
3 Ou ZY, Liu N, Chen CJ, Cheng G, He YS. Rapid and accurate genotyping of YMDD motif variants in the hepatitis B virus genome by an improved reverse dot blot method. J Clin Microbiol 2005;43:5685-9. [PMID: 16272505 DOI: 10.1128/JCM.43.11.5685-5689.2005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Jang H, Cho M, Heo J, Kim H, Jun H, Shin W, Cho B, Park H, Kim C. Oligonucleotide chip for detection of Lamivudine-resistant hepatitis B virus. J Clin Microbiol. 2004;42:4181-4188. [PMID: 15365009 DOI: 10.1128/jcm.42.9.4181-4188.2004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
5 Cheng H, Zhang HZ, Shen WA, Liu YF, Ma FC. Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli. World J Gastroenterol 2003;9:513-5. [PMID: 12632508 DOI: 10.3748/wjg.v9.i3.513] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Zhang HY, Liu LG, Ye CY, Chen CH, Hang SX, Zhu Z, Shen HY, Huang ZY, Chen WY, Xue Y. Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016). Virus Genes. 2018;54:41-47. [PMID: 29119303 DOI: 10.1007/s11262-017-1518-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yao G, Zhou X, Xu D, Wang B, Ren H, Liu J, Xu D, Macdonald L. Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int 2007;1:373-81. [PMID: 19669332 DOI: 10.1007/s12072-007-9016-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
8 Shi QQ, Dang J, Wen HX, Yuan X, Tao YD, Wang QL. Anti-hepatitis, antioxidant activities and bioactive compounds of Dracocephalum heterophyllum extracts. Bot Stud 2016;57:16. [PMID: 28597426 DOI: 10.1186/s40529-016-0133-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
9 Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients. Drug Des Devel Ther. 2013;8:13-24. [PMID: 24376343 DOI: 10.2147/dddt.s41423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]